Published in:
Open Access 01-12-2019 | Hepatocellular Carcinoma | Research article
Case-control Indian buffet process identifies biomarkers of response to Codrituzumab
Published in: BMC Cancer | Issue 1/2019
Login to get accessAbstract
Background
Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. Biomarker analysis was performed to identify a responder population that benefits from treatment.
Methods
A novel statistical method based on the Indian buffet process (IBP) was used to identify biomarkers predictive of response to treatment with Codrituzumab. The IBP is a novel method that allows flexibility in analysis design, and which is sensitive to slight, but meaningful between-group differences in biomarkers in very complex datasets
Results
The IBP model identified several subpopulations of patients having defined biomarker values. Tumor necrosis and viable cell content in the tumor were identified as prognostic markers of disease progression, as were the well-known HCC prognostic markers of disease progression, alpha-fetoprotein and Glypican-3 expression. Predictive markers of treatment response included natural killer (NK) cell surface markers and parameters influencing NK cell activity, all related to the mechanism of action of this drug
Conclusions
The Indian buffet process can be effectively used to detect statistically significant signals with high sensitivity in complex and noisy biological data
Trial registration
NCT01507168, January 6, 2012